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A PHASE 2 STUDY OF BORTEZOMIB PLUS HIGH-DOSE MELPHALAN CON-
DITIONING FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTA-
TION IN MULTIPLE MYELOMA
Nishihori, T.1, Ochoa-Bayona, J.L.1, Pidala, J.1, Shain, K.2, Baz, R.2,
Simonelli, C.M.1, Sullivan, D.1, Anasetti, C.1, Alsina, M.1 1H. Lee Mof-
fitt Cancer and Research Institute, Tampa, FL; 2H. Lee Moffitt Cancer
Center and Research Institute, Tampa, FL
Background: High-dose chemotherapy followed by autologous
HCT is a preferred primary treatment approach in multiple mye-
loma. In this study, we examine the effects of adding bortezomib
to standard high-dose melphalan in patients with newly diagnosed,
chemosensitive myeloma.
Methods: Thirty five newly diagnosed multiple myeloma patients
with responsive disease (partial response (PR) or better) to induction
therapy were enrolled to the study from 01/2010 to 06/2011. Pa-
tients received high-dose melphalan conditioning at 100 mg/m2 IV
for 2 days, immediately followed by 1 dose of bortezomib at 1.3
mg/m2 (Mel/Vel). Those patients who achieved PR post induction
were considered for tandem autologous transplant with Mel/Vel
conditioning.
Results:To date, 35 patients received autologousHCT conditioned
with Mel/Vel, and 32 are evaluable for response. Median age is 56
years (range, 25 - 72) with the following disease characteristics:
IgG (n 5 21), IgA (n 5 8), IgD (n 5 1), light chain (n 5 5). High-
risk cytogenetics/FISH were seen in 13 patients (37%). Median
beta-2 microglobulin was 3.5 (range, 1.3 – 34.8). Sixteen patients re-
ceived bortezomib-based induction, 9 patients received lenalido-
mide-based therapy and 10 received both bortezomib and
lenalidomide. Median time from initiation of induction to transplant
was 221 days (range, 134 - 664). Responses to induction therapy were
stringent CR (n 5 10), CR (n 5 4), very good partial response
(VGPR) (n 5 13), and PR (n 5 8). Median CD34 cell dose is 4.86
x 106/kg (range, 2 – 20.08). Neutrophil engraftment was achieved af-
ter a median of 11 days (range, 10 – 14) and platelet engraftment oc-
curred after a median of 16 days (range, 11 – 19). Two patients
received tandem HCT. Best responses post transplant were sCR (n
5 19), CR (n5 3), VGPR (n5 7), PR (n5 1) and progressive disease
(n 5 2). The one year progression-free survival (PFS) estimate is
77% (95%CI 0.59 – 0.95) and one year overall survival (OS) estimate
is 96% (95% CI 0.88 – 1.00) with a median follow-up of 279 days
(range, 47 – 515). We did not detect significant differences in OS
(p 5 0.69) stratified by cytogenetic/FISH risk status.
Conclusions: The combination of bortezomib and high-dose mel-
phalan (Mel/Vel) as conditioning regimen for autologous HCT is
well tolerated and appears to improve responses post transplant.
This early result is encouraging and the regimen will be examined
in expanded cohort of patients.254
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR CONSOLI-
DATION OF VGPR OR CR IN MYELOMA
Nishihori, T.1, Ochoa-Bayona, J.L.1, Pidala, J.1, Shain, K.2,
Sullivan, D.1, Baz, R.2, Anasetti, C.1, Alsina,M.1 1H. LeeMoffitt Cancer
Center and Research Institute, Tampa, FL; 2H. LeeMoffitt Cancer Center
and Research Institute, Tampa, FL
Allogeneic hematopoietic cell transplantation (HCT) from HLA-
identical siblings has been shown to prolong survival of patients with
multiple myeloma in some studies. We summarize our experience
with the safety and efficacy of allogeneic transplantation for patients
achieving VGPR or better following induction therapy containing
novel agent(s). Thirteen myeloma patients with first VGPR or CR
received allogeneic HCT between July 2007 and January 2011. Me-
dian age at transplant was 45 years (range, 25 – 59), median time from
initial therapy to transplant was 236 days (range, 122 – 410). Six pa-
tients (46%) have high-risk cytogenetics/FISH. Five patients re-
ceived bortezomib plus lenalidomide induction therapy and eight
patients received bortezomib-induction. Three patients (23%) un-
derwent autologous HCT with melphalan plus bortezomib condi-
tioning (melphalan 100 mg/m2 for 2 days followed by bortezomib
1.3 mg/m2) subsequent to induction therapies to achieve furthercytoreduction prior to allogeneic HCT. Median number of prior
therapies was 2 (range, 1-2). Disease status at the time of allogeneic
HCT was stringent CR (n5 5), CR (n5 3), and VGPR (n5 5). All
patients received unmanipulated peripheral blood stem cell grafts
fromHLA-matched sibling donors (n5 5) andHLA-matched unre-
lated donors (n5 8). Six patients received fludarabine 30mg/m2 for 4
days and melphalan 70 mg/m2 for 2 days followed by a single dose of
bortezomib 1.3 mg/m2 (Flu/Mel/Vel). Seven patients received flu-
darabine 40 mg/m2 for 4 days and melphalan 70 mg/m2 for 2 days
(Flu/Mel). All patients achieved neutrophil engraftment after a me-
dian of 17 days (range, 11 - 19), and all patients achieved platelet en-
graftment after a median of 17 days (range, 12 - 21). All patients
established stable donor cell chimerism. Best responses after alloge-
neic HCT were sCR (n 5 10), CR (n 5 2) and VGPR (n 5 1). The
cumulative incidence of grades 2-4 acuteGVHDat day 100was 57%
(95% CI 0.30 – 1.00) with Flu/Mel conditioning and 33% (95% CI
0.11 – 1.00) for Flu/Mel/Vel conditioning, respectively (p 5 0.24).
One patient died ofGVHDcomplications, 1 had disease progression
and 11 remain alive, progression free with a median follow-up of one
year (range 4 months to 4 years). The one year progression-free sur-
vival estimate is 90% (95%CI 0.71 – 1.00). These initial data indicate
that allogenic transplant for myeloma in VGPR or CR is well toler-
ated. Longer follow-up is required to better assess the efficacy of al-
logeneic HCT.255
PRESENTING FEATURES OF MULTIPLE MYELOMA IN PATIENTS UNDER
THE AGE OF 50 IN NEWFOUNDLAND AND LABRADOR
Pardy, N., Tompkins, K. Memorial University of Newfoundland, St.
John’s, NL, Canada
Multiple myeloma (‘‘MM’’) is a hematological malignancy of
plasma cells with no known cure. Given the average median sur-
vival times, this disease can be a particularly devastating diagnosis
in those under age 50. In 2008, Ludwig et al. determined that
young patients with MM are more likely to present at Interna-
tional Staging System (‘‘ISS’’) stage 1 (the ‘‘Ludwig study’’).[1]
The current study was designed to determine whether, consistent
with the Ludwig study, a majority of patients under age 50 at di-
agnosis in Newfoundland and Labrador (‘‘NL’’), Canada, present
at ISS stage 1. Patients diagnosed with MM under age 50 be-
tween January 2001 and August 2011 were located using Provin-
cial transplant and cancer registries. A total of thirteen patients
were identified and analyzed, with patient characteristics and pre-
senting features listed in table 1. Young patients were more often
female, with median age at diagnosis 43 years. A majority pre-
sented with low serum albumin (53.8%), lytic lesions (69.2%),
clonality of plasma cells greater than 10 percent (61.5%) and el-
evated b2-microglobulin (69.2%). Low hemoglobin (46.4%), re-
nal insufficiency (38.5%) and hypercalcemia (7.6%) were less
common. 30.8% of patients presented at ISS stage 1, while
30.8% presented at stage 2 and 38.5% at stage 3. In contrast,
in the Ludwig study 39% of patients under age 50 presented
at ISS stage 1, 35% at stage 2 and 27% at stage 3. Limitations
of this study are the small sample size, which could be overcome
by doing a follow-up study involving other Canadian provinces.
Further, the Ludwig study compared patients under and over
the age of 50 at diagnosis. Our study examined only patients un-
der the age of 50, and compared the data to that in the Ludwig
study. This study is pertinent as presentation at a more advanced
ISS stage confers poorer prognosis. Given that a minority of pa-
tients under the age of 50 in NL are presenting at stage 1, this
has significant impact on provincial outcomes and raises impor-
tant questions as to why this is occurring. A possible answer is
that the diagnosis is overlooked in the young. A potential further
area of study is the development of a decision rule to assist phy-
sicians in determining which patients need further investigation
for MM.
[1] H. Ludwig et al,Myeloma in Patients Younger than Age 50 Pres-
ents with More Favorable Features and Shows Better Survival: An Anal-
ysis of 10 549 Patients from the International Myeloma Working Group.
Blood 111(8): 4039-47, 2008.
